Health economics and market access, built for HTA decisions.

Evidaxia is an independent health economics, market access and global health consultancy. We build economic models and evidence packages, prepare HTA and EU JCA submissions, support pricing and reimbursement, and help NGOs, charities and public health programmes measure and communicate their impact.

Our founder worked inside NICE as an HTA Technical Lead and Analyst, so we build evidence the way assessors read it. The senior person who scopes your project does the work, from the first model to the final meeting.

Yes. We support NICE, SMC, AWMSG, NCPE, CDA-AMC and EU JCA work, from early advice and PICO scoping to the dossier, clarification questions, resubmission and price negotiation.

Our work spans oncology, rare diseases, cell and gene therapy, cardiovascular, ophthalmology, respiratory, haematology and women's health, for medicines, advanced therapies, devices, diagnostics and digital health.

Yes. We help them with situation analysis, MEAL, costing, return on investment, advocacy and campaigns. We also take on pro bono partnerships with selected community organisations, charities and patient groups.

Every project starts with a free, no-obligation 30-minute call about the decision ahead. We then agree the scope, deliverables and timelines before work starts, and the senior consultant who scopes the work delivers it.

Yes. We provide policy analysis and benchmarking, stakeholder mapping, public affairs, policy briefs and consultation responses, health communications, media relations and advocacy campaigns, for companies, NGOs, governments and patient groups.

We are based in the EU and work across the UK, Ireland, Europe, Canada and the US, and with global health programmes in low- and middle-income countries.